Pfizer's combo cholesterol drug draws fire

A Harvard University researcher is urging Pfizer to split its cholesterol drugs to allow patients a better shot at improving their health. Pfizer has been under attack for considering a plan to market its new drug torcetrapib for lowering LDL, or bad cholesterol, in combination with Lipitor, which raises HDL, or good cholesterol. A number of researchers, though, say the drugs should be sold separately to provide patients with greater choices. Pfizer has been accused of proposing a combination because its patent for Lipitor will expire in 2010. Analysts say a combination pill could be worth up to $15 billion per year for Pfizer.

- read this story from the Los Angeles Times for more

ALSO: Pfizer is planning to outsource some of its IT work to India as part of a cost-saving plan. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.